NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus

Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus

Final Report

Drug Class Reviews

, MD, MPH, MSc, , PharmD, BCPS, , MPH, , MPA, HA, and , MS.

Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director
Portland (OR): Oregon Health & Science University; .

Diabetes mellitus (diabetes) is a chronic and insidious disease affecting more than 20 million Americans, approximately 7% of the population. Within the last 1 to 2 years, three new antihyperglycemic agents have been approved: pramlintide, exenatide, and sitagliptin. These agents offer mechanisms of glycemic control beyond that of "traditional" oral agents and insulin by targeting alternate gluco-regulatory receptors and hormones such as amylin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and dipeptidyl peptidase-4 (DPP-4). The purpose of this review was to compare the effectiveness and harms of newer diabetes medications for persons with diabetes mellitus.

The funding source, the Center for Evidence-based Policy, is supported by 14 organizations, including 13 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

Suggested citation:

Norris SL, Lee NJ, Severance S, Thakurta S. Drug class review on newer drugs for the treatment of diabetes mellitus. 2008.

The Agency for Healthcare Research and Quality has not yet seen or approved this report.

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

Copyright © 2008, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10605PMID: 20496447
PubReader format: click here to try


Other titles in this collection

Related information

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...